[Federal Register Volume 60, Number 202 (Thursday, October 19, 1995)]
[Notices]
[Pages 54076-54077]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 95-25886]



-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES
[Docket No. 95N-0334]


Drug Export; Atrovent (Ipratropium Bromide) Nasal Spray 
0.03%, 10 Milliliter (mL) and 30 mL

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: The Food and Drug Administration (FDA) is announcing that 
Boehringer Ingelheim Pharmaceuticals Inc., has filed an application 
requesting approval for the export of the human drug Atrovent 
(ipratropium bromide) Nasal Spray 0.03%, 10 mL and 30 mL to Canada.

ADDRESSES: Relevant information on this application may be directed to 
the Dockets Management Branch (HFA-305), Food and Drug Administration, 
rm. 1-23, 12420 Parklawn Dr., Rockville, MD 20857, and to the contact 
person identified below. Any future inquiries concerning the export of 
human drugs under the Drug Export Amendments Act of 1986 should also be 
directed to the contact person.

FOR FURTHER INFORMATION CONTACT: James E. Hamilton, Center for Drug 
Evaluation and Research (HFD-310), Food and Drug Administration, 7520 
Standish Pl., Rockville, MD 20855, 301-594-3150.

SUPPLEMENTARY INFORMATION: The drug export provisions in section 802 of 
the Federal Food, Drug, and Cosmetic Act (the act) (21 U.S.C. 382) 
provide that FDA may approve applications for the export of drugs that 
are not currently approved in the United States. Section 802(b)(3)(B) 
of the act sets forth the requirements that must be met in an 
application for approval. Section 802(b)(3)(C) of the act requires that 
the agency review the application within 30 days of its filing to 
determine whether the requirements of section 802(b)(3)(B) have been 
satisfied. Section 802(b)(3)(A) of the act requires that the agency 
publish a notice in the Federal Register within 10 days of the filing 
of an application for export to facilitate public participation in its 
review of the application. To meet this requirement, the agency is 
providing notice that Boehringer Ingelheim Pharmaceuticals Inc., 900 
Ridgebury Rd., Ridgefield, CT 06877, has filed an application 
requesting approval for the export of the human drug Atrovent 
(ipratropium bromide) Nasal Spray 0.03%, 10 mL and 30 mL to Canada. 
This drug product is used for the symptomatic relief of rhinorrhea 
associated with allergic or non-allergic perennial rhinitis. The 
application was received and filed in the Center for Drug Evaluation 
and Research on September 28, 1995, which shall be considered the 
filing date for purposes of the act.
    Interested persons may submit relevant information on the 
application to the Dockets Management Branch (address above) in two 
copies (except that individuals may submit single copies) and 
identified with the docket number found in brackets in the heading of 
this document. These submissions may be seen in the Dockets Management 
Branch between 9 a.m. and 4 p.m., Monday through Friday.
    The agency encourages any person who submits relevant information 
on the application to do so by October 30, 

[[Page 54077]]
1995, and to provide an additional copy of the submission directly to 
the contact person identified above, to facilitate consideration of the 
information during the 30-day review period.
    This notice is issued under the Federal Food, Drug, and Cosmetic 
Act (sec. 802 (21 U.S.C. 382)) and under authority delegated to the 
Commissioner of Food and Drugs (21 CFR 5.10) and redelegated to the 
Center for Drug Evaluation and Research (21 CFR 5.44).

    Dated: October 4, 1995.
Betty L. Jones,
Deputy Director, Office of Compliance, Center for Drug Evaluation and 
Research.
[FR Doc. 95-25886 Filed 10-18-95; 8:45 am]
BILLING CODE 4160-01-F